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It is a matter of debate whether hypothalamic somatostatin (SRIH) secretion in acromegaly is
preserved and still regulated by the physiological feedback mechanisms of growth hormone (GH)
and insulin-like growth factor I. To gather further information on this, the reproducibility of plasma
GH changes induced by growth hormone-releasing hormone (GHRH) administration was evaluated in
15 acromegalic patients. There was a highly significant correlation between the peak/basal ratio (P/B)
GH response in the 15 patients administered GHRH on two separate occasions (r = 0.99, p <0.001).
The test was performed also before and after the administration of drugs able to inhibit or stimulate
hypothalamic SRIH release, by activating (pyridostigmine) or inhibiting (pirenzepine) cholinergic
pathways, respectively. The GHRH-induced GH response (P/B = 2, range 1.1\p=n-\26.1)was increased
significantly by pyridostigmine pretreatment in 30 patients (P/B = 2.6, range 1.3\p=n-\34.8;p = 0.0045).
In nine out of 30 patients an increase of greater than 2sd of within-subject GHRH variability was
observed in response to GHRH plus pyridostigmine when compared to GHRH alone. An inverse
correlation (r = \m=-\0.37,p <0.05) was observed between GH response to GHRH alone and after
pyridostigmine pretreatment. On the contrary, no change of GHRH-induced GH response was
observed in 12 patients after pirenzepine pretreatment (P/B =1.9, range 1.1\p=n-\5and P/B = 2, range
1.3\p=n-\6without and after pirenzepine pretreatment, respectively). These data suggest that in
acromegaly the somatostatinergic tone does not seem to fluctuate, and that it can be inhibited often
by cholinergic pathway activation but not increased further by cholinergic suppression.
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The GHRH-induced GH response has been shown to be
variable among acromegalie patients (1,2), but we are
not aware of any studies on the intrasubject reprodu¬
cibility of this response. As the wide intrasubject
variability observed in GHRH-induced GH levels in
normal subjects has been attributed to the fluctuations
of hypothalamic somatostatin (SRIH) tone (3), gather¬
ing data on this matter could, in fact, indirectly shed
some light on the somatostatinergic tone in acrome¬
galy, which is still a matter of debate.
A reduction of hypothalamic SRIH secretion was
suggested as being the primary cause of acromegaly (4).
Recently, attention has focused on primary pituitary
pathogenesis of this disease, the hypothesis being that
an excess of hypothalamic SRIH occurs provided that
the short-loop feedback between GH and SRIH secretion(5) is well functioning. There is, indeed, evidence that
hypothalamic control of GH secretion may be preserved
in acromegalie patients, because their GH levels often
increase after stimuli such as arginine, insulin and
exercise, which modulate GHRH and/or SRIH release at
the hypothalamic level (6).
* Deceased.
To obtain information on somatostatinergic tone in
acromegaly, we studied the reproducibility of the GH
response to GHRH in acromegalie patients. Somatosta¬
tinergic tone also was evaluated indirectly in a larger
group of patients after pharmacological manipulations:
GHRH-induced GH secretion was studied after the
administration of pyridostigmine (Pyr), putatively
inhibiting SRIH secretion by activation of cholinergic
pathways (7), and pirenzepine (Pz), an antimuscarinic
drug that is supposed to stimulate SRIH secretion (8).
Materials and methods
Patients
Thirty patients (11 males and 19 females, aged 22-
76 years, median 51) with active acromegaly (according
to increased GH, not suppressible by glucose load, and
high IGF-I levels) entered the study. Individual demo¬
graphic and clinical data are reported in Table 1. No
patient was hyperprolactinemia Any drug treatment
aimed at lowering GH hypersécrétion or potentially
capable of interfering with GH secretion was withdrawn
at least 4 weeks before the start of the study, as part of
Table 1. Demographic and clinical data.
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aN: normal; M: macroadenoma; y: microadenoma; E: empty sella;
respectively.bTNS: trans-sphenoidal; TC: trans-cranial.
CA: hydrocortisone; T: L-thyroxine; G: gonadal steroids.
and '-' indicate the presence or not of suprasellar extension,
periodic off-treatment evaluation of disease. Each patient
gave informed consent after full explanation of the
purpose of the study and the procedures followed were
in accordance with the Helsinki Declaration of 1975 as
revised in 1983.
Protocol
Fifteen patients (cases 1-13, 15, 22) underwent the
GHRH (1-44) test (UCB, Bruxelles; 100 pg iv at time 0)
twice on different days (at least 2 days apart, range 2
days-21 months). No patient was submitted to major
procedures (neurosurgery or radiotherapy) between the
two tests.
All 30 patients randomly underwent tests with
GHRH alone and after pretreatment with Pyr (120 mg
administered po60min before GHRH injection), each
test being separated by at least 7 days. In 12 of these
patients (cases 1-12) the GHRH test was repeated after
pretreatment with Pz (50 mg administered po 120 min
before GHRH injection). In our preliminary study these
doses of Pyr and Pz were effective in increasing or
lowering, respectively, plasma GH response to GHRH in
normal subjects, without major side effects. At 08.00 h
after an overnight fast and rest, while the patients were
supine and awake, an indwelling needle was inserted in
an antecubital vein and kept patent by slow saline
infusion. After two basal samples (-30 min, Omin),
GHRH was injected and blood samples were collected
after 15, 30, 45, 60, 90 and 120 min. When Pyr or Pz
were given, two basal plasma samples were collected at
-30 and Omin before drug administration and there¬
after every 30 min until GHRH injection. Blood samples
collected at 15-min intervals over a period of 120 min
during saline infusion on another day were used as
control.
In each blood sample, GH, PRL and TSH values were
assayed.
All patients had previously undergone acute tests
with TRH (200/xg iv), bromocriptine (2.5mgpo) and
octreotide (100/igsc), with methods described pre¬
viously (3).
Methods
Growth hormone, PRL, TSH and IGF-I were assayed in
duplicate by immunoenzymatic assay, kinetic enzyme
immunometric assay, solid phase two-site fluoroimmu-
nometric assay and RIA after acid-ethanol extraction,
respectively. Plasma hormone concentrations were
determined in each patient in a single run. Reagents
were provided by Sorin (Saluggia, Italy) for GH, DPC(Los Angeles, CA, USA) for PRL, Wallac-Oy (Turku,
Finland) for TSH and Nichols Institute (San Juan
Capistrano, CA, USA) for IGF-I. Standards were
calibrated against first IS 80/505 (lng = 2 µ  ) for
GH, WHO first IRP 75/504 for PRL, WHO second IRP
80/558 for TSH and WHO IRP 87/518 for IGF-I.
Normal values for adult patients in our laboratory are
less than 5 µg/l for GH, less than 18 µ-g/l for PRL, 0.1-
3.5 mU/1 for TSH and 123-463 µg/l for IGF-I. Within-
assay coefficients of variation for GH were 4.1% and
4.8% at GH concentrations near 10 and 2 5/¿g/1,
respectively.
Statistical analysis
Values were expressed as medians and ranges. The GH
responses to GHRH, GHRH plus Pyr and GHRH plus Pz
were evaluated as the ratio between peak and baseline(P/B).
Analysis of the results was performed by the following
tests: reproducibility of the GHRH test was evaluated by
the Pearson correlation, comparison of P/B ratios by the
Wilcoxon rank test, comparison of results obtained
among various subgroups of patients by the Mann-
Whitney or Fisher test (for numerical and dichotomic
results, respectively) and correlations by the Spearman
test, as appropriate. Owing to wide variations, the
comparison between P/B ratios after each test was
repeated also after log transformation of raw data;
 
< 0.05 was considered to be statistically significant.
Results
No significant differences among basal GH levels were
observed before GHRH administrations or during saline
infusion (data not shown).
Growth hormone-releasing hormone elicited a sig¬
nificant increase in GH levels as compared to baseline
values (basal 21.8µg/l, range 6-220; peak 48/xg/l,
range 8.3-634;  < 0.00001). An analytical evaluation
of the individual responses to GHRH showed a wide
intersubject variability, ranging from 1.1 to 26.1(expressed as P/B).
On the contrary, a highly significant correlation was
observed between P/B GH response in the 15 patients
administered GHRH on two separate occasions(r = 0.99,
 
< 0.001) (Fig. 1). Basal GH levels were no
different between the two tests. These data were utilized
for evaluation of pharmacological manipulation of
Il test
P/B
10
r = 0.99
 
< 0.001
1 io I test
P/B
Fig. 1. Reproducibility of GHRH test, expressed as peak/basal (P/B)
ratio, in 15 patients.
cholinergic pathways. After transforming the results
of the second GHRH test into a ratio of the first, the
mean and standard deviation of this ratio were
calculated; the sd was 0.22 for the ratio of P/B GH levels.
Pretreatment with Pyr did not change basal GH levels
but significantly increased the GH response to GHRH (P/
 
= 2, range 1.1-26.1 for GHRH alone and P/B = 2.6,
range 1.3-34.8 for GHRH plus Pyr;  = 0.0045). In 9
out of 30 patients (cases 1, 4, 7-10, 16, 19, 20),
analytical evaluation of these data showed a potentia-
tion of GH response to GHRH after the Pyr pretreatment
greater than 2sd (i.e. greater than 0.44) when
compared to the response to GHRH alone, whereas
the opposite phenomenon was observed in only one
patient (case 21) (Fig. 2). No significant difference was
observed in responsiveness to Pyr pretreatment among
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Fig. 2. Individual data of GH expressed as peak/basal (P/B) ratio in 30
patients (log scale). Each line is for a single patient, whose case
number is reported in the lower part of the figure. Data are ranked in
increasing order according to GH response to GHRH alone (filled
circles). Arrows show variations in GHRH-induced P/B ratios after
pyridostigmine pretreatment. Asterisks indicate patients in whom this
variation had increased greater than 2 sd when compared to GHRH
administration alone.
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Fig. 3. Inverse correlation between GH response to GHRH alone(expressed as peak/basal (P/B) ratio on horizontal axis) and
potentiation of GHRH-induced GH response after pyridostigmine(Pyr) pretreatment (expressed as ratio between P/B after GHRH plus
Pyr and after GHRH alone on vertical axis).
patients treated previously or not by neurosurgery and/
or radiotherapy, or among patients whose GH levels
were responsive or not to acute TRH, bromocriptine or
octreotide administration. No significant difference was
observed in GH response to GHRH after Pyr pretreat¬
ment if patients were divided according to sex.
A statistically significant inverse correlation(r = -0.37,
 <0.05) was observed between GHRH-
induced GH response (evaluated as P/B) and the
potentiation of this response by Pyr pretreatment(evaluated as ratio between P/B after Pyr plus GHRH
and P/B after GHRH alone) (Fig. 3).
No correlation was found between age and GH
response to GHRH or Pyr potentiation of GHRH-
induced GH response.
No significant change was observed in GHRH-
induced GH response after pretreatment with Pz in 12
patients (P/B = 1.9, range 1.1-5 and P/B = 2, range
1.3-6 without and after Pz pretreatment, respectively).
The analytical evaluation of these data showed that in
no patient did Pz pretreatment cause inhibition of GH
response to GHRH, whereas in two patients (cases 1 and
7) an increase was observed.
No significant variation was observed in PRL and
TSH levels after each test (data not shown).
No major side effect was observed in any patient
during the tests.
Discussion
A wide intersubject variability in the GH-releasing effect
of GHRH was observed among our patients, as in
previous studies (2, 3). It is to be noted that this
response is quite reproducible in the single acromegalie
subjects of this series, as shown by the highly significant
correlation between the P/B GH response in patients
administered GHRH on two separate occasions. This is
in contrast with normal subjects, in whom a wide
intrasubject variability of GHRH-induced GH response
also has been shown and attributed to variations of
endogenous SRIH secretion (1). Thus, the first conclu¬
sion that could be drawn from our data is that SRIH
levels do not seem to fluctuate in acromegalie subjects.
However, both high and low levels of SRIH might
account for the reproducibility of the GHRH test in
acromegaly. The results obtained by pharmacological
manipulation of cholinergic pathways allowed us to
gain further insight into this topic.
In normal subjects, Pyr increases the GH response to
GHRH (9). On the basis of indirect animal studies it is
widely accepted that the stimulation of GH secretion by
the cholinergic system is mediated by an inhibition of
hypothalamic somatostatin release (7), even though
Magnan et al. (10) showed direct GHRH stimulation by
the cholinergic agonist neostigmine in sheep. Our data
are in contrast to Arvat et al. (11), who did not observe
any effect of Pyr pretreatment on GHRH-induced GH
release in acromegalie patients. If an arbitrary cut-off of
2 sd of within-subject GHRH variability is considered,
Pyr potentiation of GHRH-induced GH response
occurred in nine out of 30 patients from this series. A
certain degree of hypothalamic SRIH secretion under
inhibitory cholinergic control thus may persist in
acromegaly. The wide intersubject variability of
GHRH-induced GH response in acromegaly might, in
consequence, be related to the degree of hypothalamic
SRIH secretion. Alternatively, we may hypothesize in
this group of patients about the occurrence of Gsp
oncogene mutation that has been reported in nearly
35% of GH-secreting adenomas, with a poor response to
GHRH coupled with a good response to SRIH (12). In
our patients the significant inverse correlation observed
between the magnitude of the Pyr potentiation of
GHRH-induced GH response and the GH responsiveness
to GHRH alone (i.e. the lowest the GH response to
GHRH, the greatest the magnitude of Pyr potentiation)
is in agreement with the former suggestion.
No difference between sexes was observed in
sensitivity of the GHRH-induced GH response to Pyr
potentiation, in contrast with the data reported in
normal subjects by Barbarino and colleagues (13). It is
worthwhile noting, however, that most females in our
series were postmenopausal.
What about the non-responders, which were the
majority in our series? They do not appear to be a
separate population because there was a continuum
from the absolute non-responders up to patients whose
potentiation is of great magnitude. As neither tumor
size nor duration of disease could account for the
different pattern, we can hypothesize in the non-
responder patients a derangement of cholinergic path¬
ways or the predominance of alterations at the cellular
level, such as the density of receptors.
The antagonism exerted by Pz on cholinergic
neurotransmission did not inhibit significantly the
GH-releasing effect of GHRH. These findings are in
agreement with a previous study of acromegalie
patients by Pietschmann et al. (14), which showed
the ineffectiveness of atropine in changing the GH
response after GHRH. On the other hand, our results are
in partial conflict with the reduction of GHRH-induced
GH release observed in two out of five acromegalie
patients by Massara et al. (9) after Pz pretreatment.
In contrast with data observed in normal subjects(15), the ineffectiveness of Pz in reducing GH response
to GHRH in our study could be due to the persistence in
acromegaly of the physiological reciprocal regulation
between GH and IGF-I levels and SRIH secretion. It was,
indeed, shown in rats that hypothalamic SRIH secretion
increases after IGF-I and GH administration (16). Thus,
we may hypothesize that in acromegaly SRIH secretion,
when preserved, is already maximally activated by high
endogenous GH and IGF-I levels and therefore it cannot
be stimulated further by Pz-induced inhibition of
cholinergic tone.
In conclusion, although a derangement of the
cholinergic pathways or of the coupling between
cholinergic and somatostatinergic pathways cannot be
ruled out, our study suggests that in acromegaly SRIH
secretion does not fluctuate because it is impaired or
maximally stimulated. In the latter case, cholinergic
neurotransmission can still inhibit, but not further
stimulate, hypothalamic SRIH.
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